N-((1-((4-Chlorophenyl)Amino)-1-Oxopropan-2-Yl)Oxy)-3,5-Bis(Trifluoromethyl)Benzamide N-((1-((4-氯苯基)氨基)-1-氧代丙烷-2-基)氧基)-3,5-双(三氟甲基)苯甲酰胺
CAS 285986-88-1 MFCD85986881
化学结构图
SMILES: CC(ONC(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)Nc1ccc(Cl)cc1
化学属性
| Mol. Formula | C18H13ClF6N2O3 |
|---|---|
| Mol. Weight | 454.75084 |
| Appearance | Solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | N-((1-((4-Chlorophenyl)Amino)-1-Oxopropan-2-Yl)Oxy)-3,5-Bis(Trifluoromethyl)Benzamide |
|---|---|
| Chemical Name Translation | N-((1-((4-氯苯基)氨基)-1-氧代丙烷-2-基)氧基)-3,5-双(三氟甲基)苯甲酰胺 |
| Formula | C18H13ClF6N2O3 |
| Synonym | CCG1423; CCG-1423; CCG 1423. |
| IUPAC Name | N-((1-((4-chlorophenyl)amino)-1-oxopropan-2-yl)oxy)-3,5-bis(trifluoromethyl)benzamide |
| InChIKey | DSMXVSGJIDFLKP-UHFFFAOYSA-N |
| InChI | InChI=1S/C18H13ClF6N2O3/c1-9(15(28)26-14-4-2-13(19)3-5-14)30-27-16(29)10-6-11(17(20,21)22)8-12(7-10)18(23,24)25/h2-9H,1H3,(H,26,28)(H,27,29) |
| Canonical SMILES | O=C(NOC(C)C(NC1=CC=C(Cl)C=C1)=O)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2 |
| MDL Number | |
| CAS Number | 285986-88-1 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- CCG-1423 is a small-molecule inhibitor of RhoA transcriptional signaling. CCG-1423 displays activity in several in vitro cancer cell functional assays. CCG-1423 potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, and whereas it inhibits the growth of RhoC-overexpressing melanoma lines (A375M2 and SK-Mel-147) at nanomolar concentrations, it is less active on related lines (A375 and SK-Mel-28) that express lower levels of Rho.
相关文献及参考
- [2]. Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29.
- [3]. Chong NW, et al. STARS is essential to maintain cardiac development and function in vivo via a SRF pathway. PLoS One. 2012;7(7):e40966.
- [4]. Duggirala A, et al. cAMP-induced actin cytoskeleton remodelling inhibits MKL1-dependent expression of the chemotactic and pro-proliferative factor, CCN1. J Mol Cell Cardiol. 2014 Nov 18;79C:157-168.
- [1]. Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72.
- [1]. Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72.
- [2]. Jin W, et al. Increased SRF
